FFAR4 and polycystic ovary syndrome: The GPR120 agonist, PCOS-IR+LrB (40 mg/kg), PCOS-IR+LrB (20 mg/kg), and PCOS-IR+LrB (10 mg/kg) groups presented significantly fewer cystic follicles, more granulosa cell layers, more oocytes, and more corpora lutea (Figure 9) relative to the PCOS-IR group.